Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dolutegravir for the treatment of HIV

2 Mar 2012

Abstract excerpt

INTRODUCTION: Development of new antiretroviral drugs which are highly potent, tolerable over the long term and with a high genetic barrier to resistance is essential for the treatment of a chronic viral disease that requires life-long therapy with near-perfect medication adherence. Integrase inhibitors (INI) are a new class of antiretroviral drugs that block the action of HIV integrase, which catalyses several...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV-related health complications and treatments
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22380682
DOI: 10.1517/13543784.2012.661713

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dolutegravir for the treatment of HIVPMID 22380682Read ↗

Dolutegravir: an exciting new kid on the block.Semantic proximity Read ↗

Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?Semantic proximity Read ↗

Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIVSemantic proximity Read ↗

Dolutegravir resistance mutations: lessons from monotherapy studies.Semantic proximity Read ↗

Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance.Semantic proximity Read ↗

Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.Semantic proximity Read ↗

Dolutegravir plus lamivudine for the treatment of HIV-1 infection.Semantic proximity Read ↗

Integrase strand transfer inhibitors in the management of HIV-positive individualsSemantic proximity Read ↗

The pharmacokinetics, pharmacodynamics and pharmacogenetics of Dolutegravir and Cobicistat in the treatment of HIVSemantic proximity Read ↗

A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings.Semantic proximity Read ↗

Integrase Strand Transfer Inhibitors in HIV TherapySemantic proximity Read ↗

Integrase inhibitors in the treatment of HIV-1 infectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.